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This single-centre phase I trial was designed to determine the maximum tolerated dose of irinotecan and the recommended dose to
use in combination with a fixed dose of 5-fluorouracil (5-FU) administered as a protracted venous infusion, for the first-line treatment
of metastatic colorectal cancer (CRC). Tolerability and efficacy were secondary end points. In all, 22 patients, median age 57 years,
were treated with escalating, weekly doses of irinotecan (50, 75, 100 and 85mgm
 2) in combination with 250mgm
 2 5-FU
administered as a continuous infusion. All patients had measurable disease. The combination was well tolerated up to an irinotecan
dose of 75mgm
 2. However, three out of five patients at the 100mgm
 2 irinotecan dose level had their dose reduced due to
multiple grade 2 toxicities, and eventually one patient stopped treatment due to grade 3 diarrhoea and multiple grade 2 toxicities.
Subsequent patients were recruited at an irinotecan dose level of 85mgm
 2. The overall response rate was 55%, comprising one
complete and 11 partial responses (PRs). Six patients also achieved sustained stable disease (SD), giving a clinical benefit (complete
response/PR/SD) response of 82%. The median duration of response was 238 days (8.5 months) and median time to progression
was 224 days (8.0 months). Two patients who achieved PRs underwent partial hepatectomies. Thus, irinotecan (85mgm
 2)
combined with a continuous infusion of 5-FU (250mgm
 2) is an active and well-tolerated regimen for the treatment of metastatic
CRC. It represents an effective treatment for patients who require close supervision and support, throughout their initial exposure to
chemotherapy for this disease, and this dose combination was recommended for an ongoing phase II study.
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Colorectal cancer (CRC) is second in the league of cancer deaths in
developed countries. Approximately 25% of patients have liver
metastases at presentation and eventually 50% of newly diagnosed
patients will succumb to metastatic disease. The liver is the most
common site of disease spread, and approximately 60% of patients
with liver metastases have no evidence of extrahepatic disease
(Faivre et al, 1995). However, only 10–20% of these patients are
candidates for surgical resection (Adam, 2003), and although there
are new treatment techniques evolving, such as radiofrequency
ablation (Nordlinger and Rougier, 2002) and the regional delivery
of chemotherapy by hepatic arterial infusion (Kemeny and Ron,
1999; Kemeny, 2000), systemic chemotherapy still plays the major
role in the treatment of metastatic CRC.
The fluoropyrimidine 5-fluorouracil (5-FU) has been the
cornerstone of therapy for CRC for over 30 years and during this
time has been the subject of extensive investigation with regard to
the optimisation of its use. In combination with the biochemical
modulator leucovorin (folinic acid (FA)), it remains the reference
drug for the treatment of CRC in adjuvant, first-line and second-
line settings, with response rates of 22 and 14% for continuous
infusion and bolus 5-FU regimens, respectively (Meta-analysis
group in cancer, 1998). Modulation with FA prolongs the effect of
5-FU, conferring benefit similar to that seen with a continuous
infusion. Two of the most common combinations of 5-FU and FA
have been directly compared (de Gramont et al, 1997). The
European infusional 5-FU/FA approach (de Gramont regimen) was
deemed to be preferable to the North American bolus 5-FU/FA
strategy developed at the Mayo Clinic (de Gramont et al, 1997).
The response rate for the de Gramont regimen was significantly
higher, 32.6 vs 14.4%, than for the Mayo regimen (P¼0.0004).
Progression-free survival (PFS) was also increased, although the
median overall survival was similar (Mayo, 56.8 weeks; de
Gramont, 62 weeks, P¼0.067). The de Gramont regimen was also
better tolerated with significantly less mucositis. However, the
future of 5-FU-based therapy appears to lie in its combination with
newer agents with nonoverlapping mechanisms of action, and
several agents have demonstrated good efficacy in the treatment of
patients with metastatic CRC. These agents include the topoi-
somerase-I inhibitor irinotecan (CPT-11) (Wiseman and Mark-
ham, 1996) and the platinum compound oxaliplatin (Wiseman
et al, 1999). In phase II/III studies, irinotecan has demonstrated
consistent antitumour activity when used as second-line therapy in
5-FU-resistant metastatic disease, with response rates in the range
11–23% (Wiseman and Markham, 1996). Irinotecan has also
demonstrated a significant survival advantage with better quality
of life in two phase III studies comparing irinotecan with best
supportive care (Cunningham et al, 1998) and with infusional
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l5-FU/FA (Rougier et al, 1998) following progression on 5-FU-
based therapy. The first-line, single-agent activity of irinotecan
(Conti et al, 1996; Pitot et al, 1997; Rougier et al, 1997), coupled
with its novel mechanism of action, led to its development in
combination with 5-FU-based regimens for the first-line therapy of
metastatic CRC. Two pivotal phase III trials, one in Europe
(Douillard et al, 2000) and the other in the US (Saltz et al, 2000),
investigated the efficacy of irinotecan in combination with one of
two infusional 5-FU/FA regimens (AIO or de Gramont) (Douillard
et al, 2000) or a bolus 5-FU/FA regimen (Saltz et al, 2000). The
efficacy results for the two trials were remarkably similar with
significant improvements in response rates, time to progression
(PFS), and overall suvival for the irinotecan/5-FU/FA combination
arms of both trials when compared with the corresponding 5-FU/
FA control arms. The most significant finding from both trials was
that irinotecan, in combination with 5-FU/FA, irrespective of the
5-FU/FA regimen used, conferred a significant survival advantage.
As a result, irinotecan in combination with 5-FU/FA was approved
for the first-line therapy of advanced and metastatic CRC in both
Europe and the US. More recently, continuous infusional 5-FU
alone (the Lokich regimen) has been shown to be equivalent to the
5-FU/FA de Gramont regimen in terms of overall survival
(Maughan et al, 2002). The Lokich regimen was generally well
tolerated, although there was a greater incidence of hand–foot
syndrome (HFS) compared with the de Gramont regimen.
However, patient quality of life (QOL) was similar with both
regimens. Importantly, the Lokich regimen could be administered
for half of the cost of the de Gramont regimen (Hale et al, 2002).
Thus, the present study aimed to identify the optimal dose of
irinotecan for use in combination with the Lokich regimen of
infusional 5-FU alone (i.e. without FA) for the treatment of
patients with metastatic CRC. It was also postulated that the
tolerability would be improved by a small but regular dose of
irinotecan. Response rates, to ensure that efficacy was maintained,
and toxicity data were also recorded.
MATERIALS AND METHODS
Patient selection
Patients were eligible for inclusion in this single-centre, phase I,
open-label, dose-escalation trial if they had histologically con-
firmed, advanced adenocarcinoma of the colon or rectum, with
inoperable, measurable, metastatic disease (synchronous or
recurrent). Selection criteria included: age X18 years, Karnofsky
performance status (PS) X70 and a life expectancy of 3 months.
Patients were required to have adequate haematological function
(haemoglobin X10gl
 1, neutrophils X1.5 10
9l
 1, platelet count
X150 10
9l
 1), acceptable hepatobiliary function (serum bilir-
ubin o1.25 upper limit of normal (ULN), alkaline phosphatase
o5 ULN, aspartate aminotransferase o3 ULN) and adequate
renal function (estimated Cockcroft clearance 450mlmin
 1).
Patients were excluded if they had received prior chemotherapy
for metastatic disease or adjuvant chemotherapy within the 6
months prior to study entry, had a concurrent uncontrolled
medical illness or previous or current malignant disease likely to
interfere with protocol treatments and comparisons. Patients could
not have partial or complete bowel obstruction, chronic diarrhoea
or inflammatory bowel disease, any confirmed abnormality of
biliary transport, previous transplantation surgery or a recent
history of uncontrolled angina or cardiac arrhythmias. The trial
was conducted with full local ethical committee approval accord-
ing to the accepted standards of good clinical practice and in
agreement with the latest version of the Declaration of Helsinki. All
patients provided written informed consent. Pretreatment baseline
evaluations included a complete medical history and physical
examination, complete blood cell count and blood chemistry plus
complete tumour assessment both radiologically and by a tumour
marker (carcinoembryonic antigen (CEA)).
Treatment and dose escalation
Treatment was commenced as soon as possible after registration
and within 4 weeks of the assessments for eligibility and disease
evaluation. Initially, 5-FU was administered as a continuous,
protracted infusion, at a dose of 200mgm
 2day
 1, for 2 weeks. If
grade 0 or 1 stomatitis or HFS were the only toxicities to occur,
then the 5-FU dose was increased to 250mgm
 2day
 1 for the
remainder of the trial unless further toxicity occurred that
required a dose reduction.
The starting dose of irinotecan was 50mgm
 2 administered as a
30-min infusion once weekly. The planned dose levels were 50, 75,
100 and 125mgm
 2, with increases in the weekly dose to be made
in a step-wise fashion in cohorts of three patients. Intrapatient
dose escalation was not allowed. All patients were assessed weekly
for both haematological and nonhaematological toxicity according
to the National Cancer Institute-Common Toxicity Criteria (NCI-
CTC v 2). Patients could only be entered at the next dose level if no
dose-limiting NCI-CTC grade 3 or 4 toxicity was observed. If one
of the three patients developed grade 3 or 4 nonhaematological
toxicity (e.g. diarrhoea, vomiting, infection) within eight cycles
from the start of the study, a further three patients were enrolled at
that dose level. Similarly, if one patient developed grade 4
haematological toxicity, a further three patients were enrolled at
that dose level. In the absence of further incidences of grade 3/4
toxicity in the expanded cohort, patients could be enrolled at the
next dose level. If all three patients at a particular dose level of
irinotecan developed significant haematological or nonhaemato-
logical toxicity, treatment was stopped and the dose level below
was taken as the MTD. If patients developed grade 3 or 4 stomatitis
or HFS, then the 5-FU dose was reduced by 50mgm
 2.
Chemotherapy was administered for eight cycles prior to re-
assessment of measurable metastatic disease. One cycle was
defined as 1 week of chemotherapy with irinotecan on day 1 and
continuous infusion of 5-FU. In patients who responded or who
developed stable disease (SD), the treatment was continued for a
further eight cycles, and the response assessment then repeated. If
a patient continued to have SD or a response, then treatment could
be continued for a further eight cycles, that is, up to a maximum of
24 cycles of chemotherapy. Treatment was discontinued in the case
of disease progression, unacceptable toxicity or withdrawal of
patient consent. Concomitant medication included prophylactic
antiemetics (dexamethasone 8mg and ondansetron 8mg both
intravenously (i.v.)), with the irinotecan infusion followed by
metoclopramide 10–20mg orally every 4h as required. Some
patients also required 24–48h of ondansetron (8mg bid) and
dexamethasone (4–8mg bid) if nausea was a problem. Delayed
diarrhoea was treated early and aggressively with loperamide, with
the addition of oral ciprofloxacin if it persisted for more than 24h.
Toxicity assessment and evaluation of response
Patients were seen weekly, when their symptom control was
assessed and they were subjected to a physical examination. A
complete blood count and biochemistry profile was also
performed. Patients were assessed every 3 weeks using the tumour
marker CEA, and the first, last and lowest CEA levels during the
study were recorded.
Tumour response was assessed radiologically every eight cycles.
All radiological assessments were conducted using the same
method employed for the primary assessment. Most patients had
CT scans; however, in some patients disease was followed by chest
X-ray (CXR) and/or ultrasound if the tumours could be clearly
visualised using this method (CT: 14 patients, ultrasound liver: six
patients, CXR: two patients). Assessment without CT scans was
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phase I study was to determine the dose/schedule to take forward
to the phase II part of the study. Apart from one subject, all
patients who received 85 or 100mgm
 2 were assessed using CT
scans. All of the radiological investigations were reviewed at the
end of the study by a single consultant radiologist without the
benefit of the original reports. Any major discrepancies were re-
checked and these measurements were used in this study. All
responses were reported according to World Health Organisation
criteria. The date of relapse was taken to be the date of radiological
confirmation of relapse. For responders, the duration of response
was taken from the time of the start of treatment to the time of first
documented disease progression. For all patients, time to
progression was the time from the start of treatment to the time
of documented disease progression.
RESULTS
Between 8 May 2001 and 23 July 2002 (14 months), 22 patients (15
males and seven females), with confirmed measurable, metastatic
CRC, were included into this single-centre, phase I dose-escalation
trial. The demographic and baseline disease characteristics of the
patients at study entry are summarised in Table 1. Seven patients
had metastasis to the liver only, two to the lung only and one to
lymph nodes only. All the remaining patients had multiple sites of
disease involvement. Overall, 17 out of 22 patients had measurable
liver disease, 12 out of 22 measurable lung disease and five out of
22 measurable lymph node disease. All patients were evaluable for
safety, toxicity and response.
In total, 397 cycles of irinotecan therapy were administered to 22
patients. All patients received both irinotecan and 5-FU at each
dose level. Seven patients completed 24 weeks of therapy. Six
patients stopped treatment due to progressive disease (PD),
four due to toxicity (one of whom went on to have a liver
resection), four were planned and one patient underwent a liver
resection.
Maximum tolerated dose
Three patients received a total of 39 cycles of irinotecan therapy at
the 50mgm
 2 dose level, and six patients received 110 cycles of
irinotecan therapy at the 75mgm
 2 dose level for irinotecan.
There were no dose reductions at either dose level, but five and 13
cycles were delayed at the 50 and 75mgm
 2 dose levels,
respectively, due to toxicity or patient choice (i.e. holidays,
Table 2). One patient developed grade 3 nausea and vomiting
at the 75mgm
 2 dose level, necessitating a week’s delay and
the need for improved antiemetics. At the 100mgm
 2 irinotecan
dose level, 106 cycles of irinotecan therapy were administered
to five patients (Table 2). At this dose level, all five patients
had dose delays during 17 cycles, and three out of five patients
had dose reductions during 46 cycles. One patient stopped
treatment due to grade 3 diarrhoea and multiple grade 2 toxicities.
The other four patients all had multiple grade 2 toxicities, in
particular, lethargy and diarrhoea (Table 3), and it became
clear that this dose level was not well tolerated. In view of the
unacceptable level of toxicity observed at the 100mgm
 2
dose level of irinotecan, a new ethical committee approval
for a lower dose was applied for, and all subsequent patients
received irinotecan at a dose of 85mgm
 2. The use of multiple
grade 2 toxicities in the determination of the MTD was considered
to be a practical approach and one that provided a realistic
measure of tolerability. The occurrence of several grade 2
toxicities can have a profound impact on the ability and
willingness of patients to continue with therapy. This dose was
chosen because it represented only a small increase over the
apparently acceptable 75mgm
 2 dose level. At the 85mgm
 2
irinotecan dose level, 142 cycles of irinotecan therapy were
administered to eight patients.
Toxicity assessments
The combination of irinotecan and continuous infusion 5-FU was
well tolerated up to an irinotecan dose level of 100mgm
 2
(Table 3). No patient at the 50mgm
 2 dose level experienced any
grade 3 toxicities. One patient stopped treatment after nine cycles
of therapy because of progressive disease and one patient stopped
therapy at cycle 16 to undergo a successful right hemihepatectomy.
This patient eventually developed pulmonary metastases. One
patient developed grade 3 nausea and vomiting at the 75mgm
 2
dose level, necessitating a week’s delay after cycle 9 and the
need for improved antiemetics. Two patients stopped treatment
early because of progressive disease and the remaining patients
stopped treatment after 24 cycles. At the 100mgm
 2 dose level,
two out of the five patients treated experienced grade 3/4 toxicities
(grade 3 diarrhoea in one patient and grade 4 thrombosis in one
patient). The patient with grade 3 diarrhoea stopped treatment at
cycle 16 and subsequently went on to undergo a liver resection.
This patient is well and is considered to have achieved a complete
response (CR) 8 months after stopping chemotherapy. At the
revised irinotecan dose level of 85mgm
 2, one of the eight patients
treated experienced grade 3 cardiac toxicity, considered to be
related to 5-FU, and the treatment was stopped at week 4. One
patient had grade 3 weight loss, while another two patients treated
at this dose level experienced grade 2 5-FU toxicity: one patient
had the 5-FU dose reduced after 3 weeks to 200mgm
 2 and the
other patient did not have the 5-FU dose stepped up to
250mgm
 2. Overall, irinotecan-related grade 3/4 toxicity was
seen in four patients. One patient at 75mgm
 2 developed
grade 3 nausea and vomiting, while one patient at 100mgm
 2
developed grade 3 diarrhoea. The other two grade 3/4 toxicities
(cardiac and thrombosis) were not felt to be related to the
escalating doses of irinotecan. With the exception of 5-FU-induced
cardiac toxicity (cycle 4), all grade 3/4 toxicities occurred after
cycle 9.
Table 1 Patient characteristics
No. of patients 22
Median age, years (range) 57 (34–70)
Sex (M/F) 15/7
Primary tumour site
Colon 5
Rectum 11
Rectosigmoid 6
Karnofsky performance status
100 2
90 16
80 3
70 1
o70 0
No. of sites of metastatic disease
11 0
411 2
Sites of metastatic disease
Liver 7
Lung 2
Liver and lung 8
LN 1
Liver and LN 2
Lung and LN 2
LN¼lymph node.
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Out of the 22 patients, 12 achieved a response (one CR and 11
partial response (PR)) to yield an overall response rate of 55%.
Responses according to irinotecan dose level are shown in Table 4.
Six patients had SD and the clinical benefit to this cohort was 82%
(CRþPRþSD). The overall median duration of response was 238
days (8.5 months). There was an interesting correlation between
radiological response and CEA change. Altogether, 92% of patients
(11 out of 12) who responded to this treatment developed a greater
than 50% reduction in CEA value. On the other hand, only one of
the four patients whose disease progressed achieved at least a 50%
reduction in CEA. The situation for patients with SD was less clear.
These data therefore suggest that CEA provides a guide to outcome
in those patients who respond well or progress on treatment.
However, no firm conclusions can be made from this cohort of
only 22 patients. The median time to progression was 224 days.
DISCUSSION
Irinotecan is routinely administered intravenously either as a
single agent (Cunningham et al, 1998; Rougier et al, 1998;
Rothenberg et al, 1999; Van Cutsem et al, 1999) or in combination
with bolus or infusional 5-FU/FA regimens, using a variety of
different schedules (Douillard et al, 2000; Saltz et al, 2000), for the
treatment of advanced CRC. The objective response rate of 55%
and time to progression of 8 months obtained in the present study
compare favourably with the response rates of between 39 and 49%
and times to progression of approximately 7 months reported for
irinotecan in combination with 5-FU/FA in the two pivotal phase
III trials. Also, a clinical benefit response was observed in 82% of
patients. The dose-limiting toxicities (DLTs) following irinotecan
therapy, irrespective of schedule, are diarrhoea or diarrhoea and
neutropenia (Vanhoefer et al, 2001). Severe grade 3/4 diarrhoea
and neutropenia are estimated to occur in approximately 20% of
patients. The DLTs in the present study were diarrhoea and
lethargy, consistent with those expected for this combination
(Douillard et al, 2000; Saltz et al, 2000). There were no treatment-
related deaths and there was a very low level of neutropenia (seven
instances at grade 2 in 228 cycles; none at grade 3/4). Eight patients
(36%) experienced grade 1 (six patients) or grade 2 (two patients)
HFS attributable to treatment with continuous infusion of 5-FU.
The 85mgm
 2 dose level was well tolerated with considerably less
diarrhoea and lethargy than the 100mgm
 2 dose level (Table 3).
Only one episode of grade 3 toxicity related to the chemotherapy
was found in the 100mgm
 2 cohort (five patients), and under
normal circumstances this would have been deemed to be
acceptable and a dose escalation would be considered. However,
it became obvious that patients were not coping with this level of
treatment and were experiencing many grade 2 toxicities. At this
point, concerns were being raised in North America about the Saltz
regimen (Rothenberg et al, 2001; Sargent et al, 2001) and it was
therefore decided to reduce the irinotecan dose in this study. We
Table 2 Irinotecan dose escalation
Irinotecan cycles (n) Dose reduction (n) Dose delay (n)
Dose of
irinotecan
(mgm
 2)
No. of
patients Total
Median
(range) Patients Cycles Patients Cycles
Median
dose intensity
up to eight
cycles (%)
Median
dose intensity
up to 16 cycles
and 48 cycles
(%)
50 3 39 13 (10–15) 0 0 2 5 100 74.9
75 6 110 18 (7–24) 0 0 4 13 79.4 76.7
100 5 106 21 (16–24) 3 46 5 17 68.7 66.0
85 8 142 18 (4–24) 0 0 5 17 88.9 84.2
Total/overall 22 397 3 46 16 52 87.5 76.3
Table 3 Worst toxicity per patient (all cycles) by irinotecan dose level
considered related to irinotecan in combination with continuous infusion 5-
FU
Dose of irinotecan (mgm
 2)
50 75 100 85
Number of patients 3 6 5 8
Number of cycles 39 110 106 142
NCI-CTC toxicity grade 2 3 4 2 3 4 2 3 4 2 3 4
Toxicity
Diarrhoea 3 3 8 1 3
Weight loss 1 2 1 2
Neutropenia 0 4 0 3
Leucopenia 0 5 0 8
Lethargy 1 0 8 1
Anaemia 1 13 1 5
Stomatitis 1 0 1 0
Cardiac toxicity 0 0 0 0 1
a
ALP 5 3 0 0
Bilirubin 1 2 1 0
HFS
b 0 002
Nausea
c 00 1 0 1
Thrombosis 1 0 0 1 0
NCI-CTC¼National Cancer Institute-Common Toxicity Criteria; ALP¼alkaline
phosphatase; HFS¼hand-foot syndrome.
aRelated to 5-FU infusion.
bSix patients had
grade 1 HFS.
c11 patients had grade 1 nausea.
Table 4 Antitumour efficacy
Starting dose of irinotecan (mgm
 2)
Response 50 (n¼3) 75 (n¼6) 100 (n¼5) 85 (n¼8)
Complete response — — 1 —
Partial response 2 2 3 4
Stable disease — 2 1 3
Progressive disease 1 2 — 1
Objective response rate 55%
Clinical benefit (CR/PR/SD)
(22 evaluable patients)
82%
Median duration of response
(n¼12)
238 days
Median time to progression
(n¼22)
224 days
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need to look at toxicity as a whole rather than simply the number
of patients with grade 3 or 4 toxicities. It is noteworthy that grade
3/4 toxicities tended to present late in the study (cycles 9–19),
suggesting a cumulative toxic effect. The data from the MRC
CRO6B study showed that patients had more toxic effects and
serious adverse events if treatment was given continuously rather
than intermittently (Maughan et al, 2003). Our findings are
therefore in agreement with this study and are consistent with the
belief that patients with advanced CRC fair less well the longer they
receive continuous chemotherapy. It is also important to consider
that, in the case of some phase I studies, escalation to the next dose
level is sometimes made after only one cycle of treatment. This
may be a little too early to be certain that the toxicity attributed to
the previous dose level is acceptable. When this study was initially
envisaged, it was felt that a small weekly dose of irinotecan would
be well tolerated and efficacious. This was certainly the case and
the excess cost of the irinotecan was partially reduced by the
omission of FA and the reduction in the number of infusion
pumps required to administer this treatment. The major
disadvantage of this treatment is the need for weekly visits to
hospital to receive this therapy. However, this can be an advantage
for patients who are quite symptomatic, either from the disease or
the treatment itself. These appointments allow time for frequent
review of symptom control and support. The quality of life issues
raised here have been evaluated in more detail in the follow-on
phase II study, which is near to completion.
This study commenced before the widespread availability of oral
fluoropyrimidines such as capecitabine. The advent of such drugs
is a major step forward in terms of patient acceptability and
convenience. However, the only available randomised data that
prove their efficacy are from trials where the oral agent has been
compared to bolus 5-FU regimens rather than infusional ones
(Hoff et al, 2001; Van Cutsem et al, 2001). The European infusional
5-FU/FA approach, pioneered by de Gramont et al (1997), was
found to be better than the North American bolus 5-FU/FA
strategy developed at the Mayo Clinic. The response rate for the de
Gramont regimen was significantly higher at 32.6% compared to
14.4% with the Mayo Clinic regimen (P¼0.0004). Progression-free
survival was also increased; however, the median overall survival
was similar (Mayo Clinic, 56.8 weeks; de Gramont, 62 weeks,
P¼0.067). The de Gramont regimen was also much better
tolerated with significantly less mucositis. Weekly low-dose
irinotecan has been shown to be well tolerated in the EORTC
40986 study where irinotecan (80mgm
 2) was combined with the
AIO infusional 5-FU regimen (Ko ¨hne et al, 2003). This phase III
randomised trial of 430 patients, which was presented at the
American Society of Clinical Oncology (ASCO) meeting in 2003,
gave a PFS of 8.8 months and an overall survival of 20.1 months.
The DLT was diarrhoea, necessitating a reduction in the dose of 5-
FU. At the lower dose, grade 3/4 diarrhoea occurred in 23% of
patients on the combined arm, compared to 16% of patients who
received just AIO. Weekly irinotecan (75mg
 2) has also been
combined with continuous capecitabine (1000mgm
 2bid
 1)
(Burris et al, 2004). As with the previous study, the main toxicity
was diarrhoea, which occurred in 17% of patients (grade 3/4). Both
of these studies emphasise that low-dose weekly irinotecan is
relatively well tolerated and the Kohne study also shows that it is
very effective. Our study, using a similar dose of irinotecan (our
recommended dose: 85mgm
 2), supports these findings. None-
theless, it is likely that the convenience and acceptability of oral
fluoropyrimidines will prevail and they will become more widely
used in combination with irinotecan and oxaliplatin at the expense
of the infusional 5-FU regimens. However, until the phase III
results of these combinations are published, showing good efficacy
and tolerability (and the funding for such regimens is made
available), weekly irinotecan and a continuous infusion of 5-FU
remains a well-tolerated and effective therapy.
In summary, the preliminary data from this study are very
encouraging both in terms of efficacy and tolerability. This is an
effective treatment for patients who require close supervision and
support, throughout their initial exposure to chemotherapy for
advanced CRC.
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